G. Seipelt

6.5k total citations · 1 hit paper
75 papers, 3.0k citations indexed

About

G. Seipelt is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Seipelt has authored 75 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Oncology, 33 papers in Hematology and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Seipelt's work include Acute Myeloid Leukemia Research (25 papers), Colorectal Cancer Treatments and Studies (25 papers) and Hematological disorders and diagnostics (14 papers). G. Seipelt is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Colorectal Cancer Treatments and Studies (25 papers) and Hematological disorders and diagnostics (14 papers). G. Seipelt collaborates with scholars based in Germany, Austria and United States. G. Seipelt's co-authors include Oliver G. Ottmann, Arnold Ganser, Salah‐Eddin Al‐Batran, Akin Atmaca, D. Hoelzer, F. Herrmann, Susanna Hegewisch‐Becker, Elke Jäger, Alexander Knuth and Stephan Probst and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

G. Seipelt

71 papers receiving 2.9k citations

Hit Papers

Phase III Trial in Metastatic Gastroesophageal Adenocarci... 2008 2026 2014 2020 2008 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
    2008 568 citations G. Seipelt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Seipelt Germany 26 1.6k 1.2k 713 611 540 75 3.0k
Dok Hyun Yoon South Korea 35 2.4k 1.5× 785 0.7× 333 0.5× 2.1k 3.5× 628 1.2× 303 4.3k
Hye Jin Kang South Korea 26 822 0.5× 461 0.4× 188 0.3× 905 1.5× 326 0.6× 120 1.8k
Emilio Iannitto Italy 29 1.3k 0.8× 637 0.5× 281 0.4× 2.4k 3.9× 198 0.4× 78 3.5k
Martina Stauch Germany 27 2.0k 1.3× 710 0.6× 266 0.4× 1.9k 3.1× 295 0.5× 86 3.4k
Patricia T. Greipp United States 27 631 0.4× 415 0.4× 972 1.4× 407 0.7× 337 0.6× 142 2.4k
M. Flesch France 23 1.8k 1.1× 620 0.5× 669 0.9× 339 0.6× 361 0.7× 72 2.6k
Frederick Hagemeister United States 27 1.7k 1.0× 603 0.5× 389 0.5× 2.3k 3.7× 201 0.4× 69 3.3k
William S. Velasquez United States 29 1.4k 0.8× 597 0.5× 459 0.6× 2.5k 4.1× 237 0.4× 58 3.5k
Eray Goekkurt Germany 22 1.5k 0.9× 992 0.8× 155 0.2× 279 0.5× 710 1.3× 100 2.3k
Jooryung Huh South Korea 33 2.3k 1.4× 330 0.3× 255 0.4× 3.0k 4.8× 524 1.0× 215 4.1k

Countries citing papers authored by G. Seipelt

Since Specialization
Citations

This map shows the geographic impact of G. Seipelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Seipelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Seipelt more than expected).

Fields of papers citing papers by G. Seipelt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Seipelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Seipelt. The network helps show where G. Seipelt may publish in the future.

Co-authorship network of co-authors of G. Seipelt

This figure shows the co-authorship network connecting the top 25 collaborators of G. Seipelt. A scholar is included among the top collaborators of G. Seipelt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Seipelt. G. Seipelt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Heinemann, Volker, Laura Fischer, Frank Gieseler, et al.. (2023). Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?. Clinical & Translational Oncology. 26(5). 1268–1272. 1 indexed citations
3.
Heinemann, Volker, Ludwig Fischer von Weikersthal, Thomas Decker, et al.. (2020). FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. British Journal of Cancer. 124(3). 587–594. 94 indexed citations
4.
Modest, Dominik Paul, Ludwig Fischer von Weikersthal, Sebastian Stintzing, et al.. (2013). FOLFIRI Plus Cetuximab Versus Folfiri Plus Bevacizumab as First-Line Treatment of KRAS-Wildtype Metastatic Colorectal Cancer: German AIO Study Krk-0306 (FIRE-3). Annals of Oncology. 24. iv22–iv22. 13 indexed citations
5.
Sehouli, Jalid, Oumar Camara, M Schmidt, et al.. (2009). Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemotherapy and Pharmacology. 64(3). 585–591. 23 indexed citations
6.
Kirchner, John P., G. Seipelt, Reinhard Heyd, C. Diétrich, & Volkmar Jacobi. (2008). Ausgedehntes Pneumoperitoneum bei Therapie eines Lymphoms mit Methotrexat und Cytosinarabinosid. DMW - Deutsche Medizinische Wochenschrift. 121(42). 1288–1291.
7.
8.
Weidmann, Eckhart, et al.. (2002). Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Annals of Oncology. 13(8). 1285–1289. 72 indexed citations
9.
Koschmieder, Steffen, W.-K. Hofmann, Joachim Kunert, et al.. (2001). TGFβ-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS. Leukemia. 15(6). 942–949. 8 indexed citations
10.
Seipelt, G., Angelika Böhme, Steffen Koschmieder, & D. Hoelzer. (2001). Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Annals of Hematology. 80(3). 170–173. 26 indexed citations
11.
Seipelt, G.. (1999). Clinical Use of Hematopoietic Growth Factors. PubMed. 50. 94–105. 2 indexed citations
12.
Kalina, Uwe, et al.. (1999). Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Experimental Hematology. 27(3). 395–400. 18 indexed citations
13.
14.
Seipelt, G., et al.. (1994). Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment. Annals of Hematology. 68(4). 167–170. 3 indexed citations
15.
Seipelt, G., et al.. (1993). Induction of TNF‐α in patients with myelodysplastic syndromes undergoing treatment with interleukin‐3. British Journal of Haematology. 84(4). 749–751. 28 indexed citations
16.
Ganser, Arnold, Oliver G. Ottmann, G. Seipelt, et al.. (1993). Effect of long-term treatment with recombinant human interleukin-3 in patients with myelodysplastic syndromes.. PubMed. 7(5). 696–701. 35 indexed citations
17.
Hess, U, A. Ganser, Schnürch Hg, et al.. (1992). MYELOKATHEXIS TREATED WITH RECOMBINANT HUMAN GRANULOCYTE‐MACROPHAGE COLONY‐STIMULATING FACTOR (rhGM‐CSF). British Journal of Haematology. 80(2). 254–256. 25 indexed citations
18.
Ganser, Arnold, G. Seipelt, & D. Hoelzer. (1991). The Role of GM-CSF, G-CSF, Interleukin-3, and Erythropoietin in Myelodysplastic Syndromes. American Journal of Clinical Oncology. 14. S34–39. 13 indexed citations
19.
Ganser, Arnold, A Lindemann, G. Seipelt, et al.. (1991). Recombinant Human Interleukin-3 in Patients with Hematopoietic Failure. Recent results in cancer research. 121. 162–172. 1 indexed citations
20.
Ganser, Arnold, A. Lindemann, G. Seipelt, et al.. (1991). Clinical Effects of Recombinant Human Interleukin-3. American Journal of Clinical Oncology. 14. S51–63. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dok Hyun Yoon Breakdown of academic impact, for papers by Hye Jin Kang Breakdown of academic impact, for papers by Emilio Iannitto Breakdown of academic impact, for papers by Martina Stauch Breakdown of academic impact, for papers by Patricia T. Greipp Breakdown of academic impact, for papers by M. Flesch Breakdown of academic impact, for papers by Frederick Hagemeister Breakdown of academic impact, for papers by William S. Velasquez Breakdown of academic impact, for papers by Eray Goekkurt Breakdown of academic impact, for papers by Jooryung Huh
Rankless by CCL
2026